On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Apixaban Superior to LMWH in Reducing Recurrence of Cancer-Associated VTE

Results from a trial presented at the 2018 ASH Annual Meeting add more support for the use of direct oral anticoagulants in patients with...

First-in-Human Trial Shows AMG 330 Is Tolerable in Relapsed/Refractory AML

AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, was generally tolerable and demonstrated anti-leukemic activity in patients with relapsed/refractory acute myeloid leukemia...

For Older Patients With CLL, Ibrutinib-Based Treatment Beats Standard Chemoimmunotherapy

Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor ibrutinib with or without rituximab was superior to standard-of-care,...

Rivaroxaban Reduces Thrombotic Risk in Patients Undergoing Cancer Treatment

Primary prevention with the direct oral anticoagulant (DOAC) rivaroxaban reduced venous thromboembolism (VTE) and VTE-related mortality in patients with cancer, according to results from...

New Sickle Cell Disease Screening Test Is Highly Accurate – and Inexpensive

In a population of young children in Uganda, a new screening test for sickle cell disease (SCD) that delivers point-of-care results and costs $2...

Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL

In patients with previously untreated chronic lymphocytic leukemia (CLL), treatment with an ibrutinib-based therapy improved progression-free survival (PFS) and overall survival (OS), compared with...

Is Daratumumab Plus Lenalidomide-Dexamethasone a New Standard for Transplant-Ineligible Myeloma?

Adding daratumumab to standard combination of lenalidomide and dexamethasone (Rd) reduced the risk of disease progression and death by 44 percent in patients with...

New Tool Provides Simple Approach to Interrupting Direct Oral Anticoagulants for Surgery

Researchers have developed a “simple, standardized, easy-to-use” strategy to guide decisions about interrupting direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) scheduled...

Can Voxelotor Offer New HOPE for Sickle Cell Disease?

Treatment with voxelotor led to a dose-dependent increase in hemoglobin (Hb) levels in patients with sickle cell disease (SCD), with most patients responding to...

Ixazomib Maintenance Prolongs Progression-Free Survival in Newly Diagnosed Multiple Myeloma

For the substantial portion of patients with multiple myeloma (MM) who relapse following autologous hematopoietic cell transplantation (AHCT), maintenance therapy with ixazomib could offer...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.